EPO and α-MSH prevent ischemia/reperfusion-induced down-regulation of AQPs and sodium transporters in rat kidney
Abstract
BACKGROUND: Ischemia-induced acute renal failure (ARF) is known to be associated with significant impairment of urinary concentrating ability and down-regulation of renal aquaporins (AQPs) and sodium transporters in rats. We tested whether treatment with erythropoietin (EPO) or alpha-melanocyte-stimulating hormone (alpha-MSH) in combination with EPO reduces the renal ischemia/reperfusion (I/R) injury and prevents the down-regulation of renal AQPs and major sodium transporters. METHODS: I/R-induced ARF was established in rats by 40-minute temporary bilateral obstruction of renal arteries, and rats were kept in metabolic cages for urine measurements. After 2 or 4 days following EPO and/or alpha-MSH treatment, kidneys were removed to determine the expression levels of AQPs and sodium transporters by semiquantitative immunoblotting. RESULTS: Rats with ARF showed significant renal insufficiency, increased urine output, and high fractional excretion of urinary sodium. Consistent with this, immunoblotting and immunocytochemistry revealed that the kidney expression of AQPs (AQP-1, -2 and -3) and sodium transporters [Na,K-ATPase, rat type 1 bumetanide-sensitive Na-K-2Cl cotransporter (BSC-1), Na/H exchanger type 3 (NHE3), and thiazide-sensitive sodium chloride cotransporter (TSC)] in ARF rats was significantly decreased compared to sham-operated control rats. In contrast, EPO treatment at the time of ischemia of rats with ARF significantly prevented the ischemia-induced down-regulation of renal AQPs and sodium transporters and in parallel improved the urinary concentrating capability and renal sodium reabsorption. Importantly, similar effects were observed following the initiation of EPO or alpha-MSH treatment 4 hours after the onset of ischemia injury. Moreover, the combination of EPO with alpha-MSH potentiated the beneficial effects of single compound treatment. CONCLUSION: EPO and/or alpha-MSH treatment significantly prevent I/R-induced injuries such as urinary-concentrating defects and down-regulation of renal AQPs and sodium transporters.
Key Biomarkers
Cited By (3)
- α-Melanocyte-Stimulating Hormone and Related Tripeptides: Biochemistry, Antiinflammatory and Protective Effects in Vitro and in Vivo, and Future Perspectives for the Treatment of Immune-Mediated Inflammatory DiseasesEndocrine Reviews
- Anti-inflammatory α-Melanocyte-Stimulating Hormone Protects Retina After Ischemia/Reperfusion Injury in Type I DiabetesFrontiers in Neuroscience · 2022
- A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injuryProceedings of the National Academy of Sciences · 2005
References (4)
- Erythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by up‐regulating Bcl‐xL expressionJournal of Neuroscience Research · 2002
- Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-κB signalling cascadesNature · 2001
- Alpha-melanocyte-stimulating hormone protects against renal injury after ischemia in mice and rats.Journal of Clinical Investigation · 1997
Related Papers
- Diabetic complications and prospective immunotherapyFrontiers in Immunology · 2023 · 2 shared tags
- Childhood Obesity: Insight into Kidney InvolvementInternational Journal of Molecular Sciences · 2023 · 2 shared tags
- More than Glucose Elimination: Additional Benefits of SGLT2 Inhibitors in Glomerular DiseasesDrugs · 2026 · 2 shared tags
- Modulation of Sirt1 and FoxO1 on Hypothalamic Leptin‐Mediated Sympathetic Activation and Inflammation in Diet‐Induced Obese RatsJournal of the American Heart Association · 2021 · 2 shared tags
- Bariatric Surgery and Its Metabolic Echo Effect on Serum Uric Acid LevelsCureus · 2024 · 2 shared tags
- Treg-Related Genes Representing a Potential Shared Biological Mechanism Between Clear Cell Renal Carcinoma and ObesityJournal of College of Physicians And Surgeons Pakistan · 2024 · 2 shared tags